Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cellectar Biosciences Inc
CLRBCurrent price
0.28 USD
-0.0094 USD (-3.23%)
Last closed
0.28 USD
Company
www.cellectar.com
ISIN
US15117F5008
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
10 635 227 USD
Yield for 12 month
-92.38 %
1Y
3Y
5Y
10Y
15Y
CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.67 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-192 375 USD
Last Year
-238 867 USD
Current Quarter
-66 021 USD
Last Quarter
–
Key Figures CLRB
1 year
3 years
5 years
10 years
EBITDA
-47 400 856 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-166.00 %
PEG Ratio
–
Return On Equity TTM
-796.67 %
Wall Street Target Price
7.67 USD
Revenue TTM
–
Book Value
-0.96 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.41 USD
Diluted Eps TTM
-1.41 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CLRB
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CLRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
22.07.2022
Dividend Date
17.07.2018
Stock Valuation CLRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-3.25
Price Book MRQ
6.86
Financials CLRB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CLRB
For 52 weeks
0.23 USD
4.45 USD
50 Day MA
1.78 USD
Shares Short Prior Month
1 159 784
200 Day MA
2.57 USD
Short Ratio
8.34
Shares Short
1 304 306
Short Percent
5.06 %
BeatStart